APO Research
Talk to an analyst

APO RESEARCH · REPORT

Durvalumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Durvalumab Market Outlook and Growth Opportunities 2026

23 December 2025192 pages

Choose your research edition.

Industry ResearchDurvalumab Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Durvalumab Industry Growth and Trends Forecast to 203277 pages · $3,450 USDMarket StructureGlobal Durvalumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Durvalumab Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Durvalumab Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Durvalumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Durvalumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Durvalumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Durvalumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Durvalumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Durvalumab market include Medimmune (AstraZeneca). among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Durvalumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Durvalumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Durvalumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Durvalumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Durvalumab Segment by Company

Medimmune (AstraZeneca)

Durvalumab Segment by Type

2.4mL Injection

10mL Injection

Durvalumab Segment by Application

Locally Advanced Urothelial Carcinoma

Metastatic Urothelial Carcinoma

Others

Durvalumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Durvalumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Durvalumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Durvalumab significant trends, drivers, influence factors in global and regions.

6. To analyze Durvalumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Durvalumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Durvalumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Durvalumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Durvalumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Durvalumab industry.

Chapter 3: Detailed analysis of Durvalumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Durvalumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Durvalumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Durvalumab Industry Trends Table 2. Durvalumab Industry Drivers Table 3. Durvalumab Industry Opportunities and Challenges Table 4. Durvalumab Industry Restraints Table 5. Global Durvalumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Durvalumab Revenue Share by Company (2021-2026) Table 7. Global Durvalumab Sales Volume by Company (k units) & (2021-2026) Table 8. Global Durvalumab Sales Volume Share by Company (2021-2026) Table 9. Global Durvalumab Average Price (US$/unit) of Company (2021-2026) Table 10. Global Durvalumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Durvalumab Key Company Manufacturing Base & Headquarters Table 12. Global Durvalumab Company, Product Type & Application Table 13. Global Durvalumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Durvalumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 2.4mL Injection Table 18. Significant Companies of 10mL Injection Table 19. Global Durvalumab Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Durvalumab Sales Volume by Type (2021-2026) & (k units) Table 21. Global Durvalumab Sales Volume by Type (2027-2032) & (k units) Table 22. Global Durvalumab Sales Volume Share by Type (2021-2026) Table 23. Global Durvalumab Sales Volume Share by Type (2027-2032) Table 24. Global Durvalumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Durvalumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Durvalumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Durvalumab Sales Value Share by Type (2021-2026) Table 28. Global Durvalumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Locally Advanced Urothelial Carcinoma Table 30. Significant Companies of Metastatic Urothelial Carcinoma Table 31. Significant Companies of Others Table 32. Global Durvalumab Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Durvalumab Sales Volume by Application (2021-2026) & (k units) Table 34. Global Durvalumab Sales Volume by Application (2027-2032) & (k units) Table 35. Global Durvalumab Sales Volume Share by Application (2021-2026) Table 36. Global Durvalumab Sales Volume Share by Application (2027-2032) Table 37. Global Durvalumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Durvalumab Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Durvalumab Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Durvalumab Sales Value Share by Application (2021-2026) Table 41. Global Durvalumab Sales Value Share by Application (2027-2032) Table 42. Global Durvalumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Durvalumab Sales by Region (2021-2026) & (k units) Table 44. Global Durvalumab Sales Market Share by Region (2021-2026) Table 45. Global Durvalumab Sales by Region (2027-2032) & (k units) Table 46. Global Durvalumab Sales Market Share by Region (2027-2032) Table 47. Global Durvalumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Durvalumab Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Durvalumab Sales Value Share by Region (2021-2026) Table 50. Global Durvalumab Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Durvalumab Sales Value Share by Region (2027-2032) Table 52. Global Durvalumab Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Durvalumab Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Durvalumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Durvalumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Durvalumab Sales by Country (2021-2026) & (k units) Table 57. Global Durvalumab Sales Market Share by Country (2021-2026) Table 58. Global Durvalumab Sales by Country (2027-2032) & (k units) Table 59. Global Durvalumab Sales Market Share by Country (2027-2032) Table 60. Global Durvalumab Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Durvalumab Sales Value Market Share by Country (2021-2026) Table 62. Global Durvalumab Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Durvalumab Sales Value Market Share by Country (2027-2032) Table 64. Medimmune (AstraZeneca) Company Information Table 65. Medimmune (AstraZeneca) Business Overview Table 66. Medimmune (AstraZeneca) Durvalumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Medimmune (AstraZeneca) Durvalumab Product Portfolio Table 68. Medimmune (AstraZeneca) Recent Development Table 69. Key Raw Materials Table 70. Raw Materials Key Suppliers Table 71. Durvalumab Distributors List Table 72. Durvalumab Customers List Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Durvalumab Product Image Figure 2. Global Durvalumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Durvalumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Durvalumab Sales (2021-2032) & (k units) Figure 5. Global Durvalumab Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Durvalumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 2.4mL Injection Image Figure 10. 10mL Injection Image Figure 11. Global Durvalumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Durvalumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Durvalumab Sales Volume Share by Type (2021-2032) Figure 14. Global Durvalumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Durvalumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Durvalumab Sales Value Share by Type (2021-2032) Figure 17. Locally Advanced Urothelial Carcinoma Image Figure 18. Metastatic Urothelial Carcinoma Image Figure 19. Others Image Figure 20. Global Durvalumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Durvalumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Durvalumab Sales Volume Share by Application (2021-2032) Figure 23. Global Durvalumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Durvalumab Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Durvalumab Sales Value Share by Application (2021-2032) Figure 26. Global Durvalumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Durvalumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Durvalumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Durvalumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Durvalumab Sales Value (2021-2032) & (US$ Million) Figure 31. North America Durvalumab Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Durvalumab Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Durvalumab Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Durvalumab Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Durvalumab Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Durvalumab Sales Value (2021-2032) & (US$ Million) Figure 37. South America Durvalumab Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Durvalumab Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Durvalumab Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Durvalumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Durvalumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Durvalumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Durvalumab Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Durvalumab Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 2.4mL Injection
  • 10mL Injection
Applications
  • Locally Advanced Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Others
Companies covered
  • Medimmune (AstraZeneca)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Durvalumab Sales Value (2021-2032)
  4. 1.2.2 Global Durvalumab Sales Volume (2021-2032)
  5. 1.2.3 Global Durvalumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Durvalumab Market Dynamics
  1. 2.1 Durvalumab Industry Trends
  2. 2.2 Durvalumab Industry Drivers
  3. 2.3 Durvalumab Industry Opportunities and Challenges
  4. 2.4 Durvalumab Industry Restraints
3 Durvalumab Market by Company
  1. 3.1 Global Durvalumab Company Revenue Ranking in 2025
  2. 3.2 Global Durvalumab Revenue by Company (2021-2026)
  3. 3.3 Global Durvalumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Durvalumab Average Price by Company (2021-2026)
  5. 3.5 Global Durvalumab Company Ranking (2024-2026)
  6. 3.6 Global Durvalumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Durvalumab Company Product Type and Application
  8. 3.8 Global Durvalumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Durvalumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Durvalumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Durvalumab Market by Type
  1. 4.1 Durvalumab Type Introduction
  2. 4.1.1 2.4mL Injection
  3. 4.1.2 10mL Injection
  4. 4.2 Global Durvalumab Sales Volume by Type
  5. 4.2.1 Global Durvalumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Durvalumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Durvalumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Durvalumab Sales Value by Type
  9. 4.3.1 Global Durvalumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Durvalumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Durvalumab Sales Value Share by Type (2021-2032)
5 Durvalumab Market by Application
  1. 5.1 Durvalumab Application Introduction
  2. 5.1.1 Locally Advanced Urothelial Carcinoma
  3. 5.1.2 Metastatic Urothelial Carcinoma
  4. 5.1.3 Others
  5. 5.2 Global Durvalumab Sales Volume by Application
  6. 5.2.1 Global Durvalumab Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Durvalumab Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Durvalumab Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Durvalumab Sales Value by Application
  10. 5.3.1 Global Durvalumab Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Durvalumab Sales Value by Application (2021-2032)
  12. 5.3.3 Global Durvalumab Sales Value Share by Application (2021-2032)
6 Durvalumab Regional Sales and Value Analysis
  1. 6.1 Global Durvalumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Durvalumab Sales by Region (2021-2032)
  3. 6.2.1 Global Durvalumab Sales by Region: 2021-2026
  4. 6.2.2 Global Durvalumab Sales by Region (2027-2032)
  5. 6.3 Global Durvalumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Durvalumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Durvalumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Durvalumab Sales Value by Region (2027-2032)
  9. 6.5 Global Durvalumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Durvalumab Sales Value (2021-2032)
  12. 6.6.2 North America Durvalumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Durvalumab Sales Value (2021-2032)
  15. 6.7.2 Europe Durvalumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Durvalumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Durvalumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Durvalumab Sales Value (2021-2032)
  21. 6.9.2 South America Durvalumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Durvalumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Durvalumab Sales Value Share by Country, 2025 VS 2032
7 Durvalumab Country-level Sales and Value Analysis
  1. 7.1 Global Durvalumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Durvalumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Durvalumab Sales by Country (2021-2032)
  4. 7.3.1 Global Durvalumab Sales by Country (2021-2026)
  5. 7.3.2 Global Durvalumab Sales by Country (2027-2032)
  6. 7.4 Global Durvalumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Durvalumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Durvalumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Durvalumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Durvalumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Durvalumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Durvalumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Durvalumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Durvalumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Durvalumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Durvalumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Durvalumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Durvalumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Durvalumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Durvalumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Durvalumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Durvalumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Durvalumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Durvalumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Durvalumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Durvalumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Durvalumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Durvalumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Durvalumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Durvalumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Durvalumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Durvalumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Durvalumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Durvalumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Durvalumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Durvalumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Durvalumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Durvalumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Durvalumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Durvalumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Durvalumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Durvalumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Durvalumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Durvalumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Durvalumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Durvalumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Durvalumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Durvalumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Durvalumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Durvalumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Durvalumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Durvalumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Durvalumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Durvalumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Durvalumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Durvalumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Durvalumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Durvalumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Durvalumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Durvalumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Durvalumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Durvalumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Durvalumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Durvalumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Durvalumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Durvalumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Durvalumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Durvalumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Durvalumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Durvalumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Durvalumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Durvalumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Durvalumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Durvalumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Durvalumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Durvalumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Durvalumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Durvalumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Durvalumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Durvalumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Durvalumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Durvalumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Durvalumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Durvalumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Durvalumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Durvalumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Durvalumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Durvalumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Durvalumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Durvalumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Durvalumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Durvalumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Medimmune (AstraZeneca)
  2. 8.1.1 Medimmune (AstraZeneca) Company Information
  3. 8.1.2 Medimmune (AstraZeneca) Business Overview
  4. 8.1.3 Medimmune (AstraZeneca) Durvalumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Medimmune (AstraZeneca) Durvalumab Product Portfolio
  6. 8.1.5 Medimmune (AstraZeneca) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Durvalumab Value Chain Analysis
  2. 9.1.1 Durvalumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Durvalumab Sales Mode & Process
  6. 9.2 Durvalumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Durvalumab Distributors
  9. 9.2.3 Durvalumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst